Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

ClinicalTrials.gov ID: NCT06770933

Public ClinicalTrials.gov record NCT06770933. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 24, 2026, 2:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Double-Masked, Randomised, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy OF Non-Proliferative Type (NPDR)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.

Study identification

NCT ID
NCT06770933
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Vantage Biosciences Ltd
Industry
Enrollment
100 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 10, 2025
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027
Last update posted
Jun 17, 2025

2025 – 2027

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
8
Facility City State ZIP Site status
Retina-Vitreous Associates Medical Group Beverly Hills California 90211 Not yet recruiting
Stanford Byers Eye Institute Palo Alto California 94303 Not yet recruiting
California Retina Consultants- Santa Barbara Santa Barbara California 93103 Not yet recruiting
Florida Retina Institute - Jacksonville Southside Jacksonville Florida 32216 Not yet recruiting
Retina Associates Elmhurst Illinois 60126 Not yet recruiting
Cumberland Valley Retina Consultants Hagerstown Maryland 21740-5940 Not yet recruiting
Erie Retina Research Erie Pennsylvania 16507 Not yet recruiting
Piedmont Eye Center Lynchburg Virginia 24502 Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06770933, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 17, 2025 · Synced Sep 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06770933 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →